dc.contributor | Universidade Federal de São Paulo (UNIFESP) | |
dc.contributor | Medicine School of São Paulo Clinical Hospital | |
dc.creator | Medeiros, Eduardo Alexandrino Servolo de | |
dc.date.accessioned | 2015-06-14T13:29:45Z | |
dc.date.accessioned | 2019-05-24T16:15:06Z | |
dc.date.available | 2015-06-14T13:29:45Z | |
dc.date.available | 2019-05-24T16:15:06Z | |
dc.date.created | 2015-06-14T13:29:45Z | |
dc.date.issued | 2002-08-01 | |
dc.identifier | Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 6, n. 4, p. 149-156, 2002. | |
dc.identifier | 1413-8670 | |
dc.identifier | http://repositorio.unifesp.br/handle/11600/1491 | |
dc.identifier | S1413-86702002000400001.pdf | |
dc.identifier | S1413-86702002000400001 | |
dc.identifier | 10.1590/S1413-86702002000400001 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/2820743 | |
dc.description.abstract | Respiratory tract infections have an important clinical and economic impact and they are the most common indication for antibiotic use in outpatient practice. This prospective, multicenter non-controlled trial assessed the efficacy and safety of gatifloxacin in the treatment of community-acquired respiratory tract infections. Patients were treated with a daily oral dose of gatifloxacin 400 mg for 7-14 days. The diagnosis of respiratory infection was made based on the clinical condition and/or radiologic findings. A total of 5,044 adult patients with community-acquired respiratory infections was treated with gatifloxacin in different centers in Brazil between March 1, 2001, and October 31, 2001. Among the 5,044 patients treated, 1,501 patients (29.76%) had community-acquired pneumonia, 756 (14.99%) had acute exacerbation of chronic bronchitis and 2,787 (55.25%) had acute sinusitis. Of the total of patients treated, 3,607 (71.51%) were considered cured, 1,261 (25%) progressed with some clinical improvement, 28 (0.56%) presented a relapse, 56 (1.11%) failed to treatment and 92 (1.82%) were unable to be evaluated. Adverse events were described in 634 (12.57%) patients. The most common adverse events were: nausea (2.24%); dyspepsia (1.86%); diarrhea (0.79%); change in taste (0.46%); insomnia and irritability (0.22%); dizziness (0.77%); headache (0.42%); allergic reaction (0.18%); Central Nervous System alterations - insomnia, agitation, anxiety - (0.46%). This study showed that the treatment of respiratory tract infections with gatifloxacin was safe and efficient and had a low incidence of adverse events. | |
dc.language | eng | |
dc.publisher | Brazilian Society of Infectious Diseases | |
dc.relation | Brazilian Journal of Infectious Diseases | |
dc.rights | Acesso aberto | |
dc.subject | Gatifloxacin | |
dc.subject | community-acquired pneumonia | |
dc.subject | acute sinusitis | |
dc.subject | acute exacerbation of chronic bronchitis | |
dc.subject | treatment of respiratory infections | |
dc.title | Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin | |
dc.type | Artículos de revistas | |